{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T04:14:39Z","timestamp":1793420079067,"version":"4.5.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T00:00:00Z","timestamp":1743033600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T00:00:00Z","timestamp":1743033600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Chinese Academy of Medical Science\uff08CAMS\uff09Innovation Fund for Medical Sciences","award":["2022-I2M-1-008"],"award-info":[{"award-number":["2022-I2M-1-008"]}]},{"name":"Chinese Academy of Medical Science\uff08CAMS\uff09Innovation Fund for Medical Sciences","award":["2023-I2M-QJ-006"],"award-info":[{"award-number":["2023-I2M-QJ-006"]}]},{"name":"the Science and Technology Department Basic Research Project of Shanxi","award":["202303021211228"],"award-info":[{"award-number":["202303021211228"]}]},{"name":"the Science and Education Cultivation Fund of the National Cancer and Regional Medical Center of Shanxi Provincial Cancer Hospital","award":["QH2023023"],"award-info":[{"award-number":["QH2023023"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-025-06358-w","type":"journal-article","created":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T04:55:16Z","timestamp":1743051316000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Spatial relationships and interactions of immune cell niches are linked to the pathologic response of muscle-invasive bladder cancer to neoadjuvant therapy"],"prefix":"10.1186","volume":"23","author":[{"given":"Wasilijiang","family":"Wahafu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xihua","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongming","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangpeng","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiongjun","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2696-5279","authenticated-orcid":false,"given":"Nianzeng","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,27]]},"reference":[{"key":"6358_CR1","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"6358_CR2","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1056\/NEJMoa022148","volume":"349","author":"HB Grossman","year":"2003","unstructured":"Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL, deVere White RW, Sarosdy MF, Wood DP Jr, Raghavan D, Crawford ED. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003;349:859\u201366.","journal-title":"N Engl J Med"},{"key":"6358_CR3","doi-asserted-by":"crossref","first-page":"5384","DOI":"10.1158\/1078-0432.CCR-14-1298","volume":"20","author":"AR de Biasi","year":"2014","unstructured":"de Biasi AR, Villena-Vargas J, Adusumilli PS. Cisplatin-induced antitumor immunomodulation: a review of preclinical and clinical evidence. Clin Cancer Res. 2014;20:5384\u201391.","journal-title":"Clin Cancer Res"},{"key":"6358_CR4","doi-asserted-by":"crossref","first-page":"12106","DOI":"10.1002\/cam4.5900","volume":"12","author":"S Han","year":"2023","unstructured":"Han S, Ji Z, Jiang J, Fan X, Ma Q, Hu L, Zhang W, Ping H, Wang J, Xu W, et al. Neoadjuvant therapy with camrelizumab plus gemcitabine and cisplatin for patients with muscle-invasive bladder cancer: a multi-center, single-arm, phase 2 study. Cancer Med. 2023;12:12106\u201317.","journal-title":"Cancer Med"},{"key":"6358_CR5","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1200\/JCO.21.01003","volume":"39","author":"TL Rose","year":"2021","unstructured":"Rose TL, Harrison MR, Deal AM, Ramalingam S, Whang YE, Brower B, Dunn M, Osterman CK, Heiling HM, Bjurlin MA, et al. Phase II study of gemcitabine and split-dose cisplatin plus pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive bladder cancer. J Clin Oncol. 2021;39:3140\u20138.","journal-title":"J Clin Oncol"},{"key":"6358_CR6","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.cell.2023.02.015","volume":"186","author":"D Wang","year":"2023","unstructured":"Wang D, Liu B, Zhang Z. Accelerating the understanding of cancer biology through the lens of genomics. Cell. 2023;186:1755\u201371.","journal-title":"Cell"},{"key":"6358_CR7","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaa6090","author":"KH Chen","year":"2015","unstructured":"Chen KH, Boettiger AN, Moffitt JR, Wang S, Zhuang X. RNA imaging. Spatially resolved, highly multiplexed RNA profiling in single cells. Science. 2015. https:\/\/doi.org\/10.1126\/science.aaa6090.","journal-title":"Science"},{"key":"6358_CR8","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/s41586-019-1049-y","volume":"568","author":"CL Eng","year":"2019","unstructured":"Eng CL, Lawson M, Zhu Q, Dries R, Koulena N, Takei Y, Yun J, Cronin C, Karp C, Yuan GC, Cai L. Transcriptome-scale super-resolved imaging in tissues by RNA seqFISH. Nature. 2019;568:235\u20139.","journal-title":"Nature"},{"key":"6358_CR9","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1038\/s41592-019-0548-y","volume":"16","author":"S Vickovic","year":"2019","unstructured":"Vickovic S, Eraslan G, Salmen F, Klughammer J, Stenbeck L, Schapiro D, Aijo T, Bonneau R, Bergenstrahle L, Navarro JF, et al. High-definition spatial transcriptomics for in situ tissue profiling. Nat Method. 2019;16:987\u201390.","journal-title":"Nat Method"},{"key":"6358_CR10","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/s43018-023-00521-2","volume":"4","author":"DE Speiser","year":"2023","unstructured":"Speiser DE, Chijioke O, Schaeuble K, Munz C. CD4(+) T cells in cancer. Nat Cancer. 2023;4:317\u201329.","journal-title":"Nat Cancer"},{"key":"6358_CR11","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.trecan.2022.04.003","volume":"8","author":"KA Tooley","year":"2022","unstructured":"Tooley KA, Escobar G, Anderson AC. Spatial determinants of CD8(+) T cell differentiation in cancer. Trend Cancer. 2022;8:642\u201354.","journal-title":"Trend Cancer"},{"key":"6358_CR12","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1038\/s41568-023-00615-0","volume":"23","author":"T Gebhardt","year":"2023","unstructured":"Gebhardt T, Park SL, Parish IA. Stem-like exhausted and memory CD8(+) T cells in cancer. Nat Rev Cancer. 2023;23:780\u201398.","journal-title":"Nat Rev Cancer"},{"key":"6358_CR13","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/nri.2017.145","volume":"18","author":"Y Huang","year":"2018","unstructured":"Huang Y, Kim BYS, Chan CK, Hahn SM, Weissman IL, Jiang W. Improving immune-vascular crosstalk for cancer immunotherapy. Nat Rev Immunol. 2018;18:195\u2013203.","journal-title":"Nat Rev Immunol"},{"key":"6358_CR14","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1016\/j.immuni.2023.08.009","volume":"56","author":"WH Fridman","year":"2023","unstructured":"Fridman WH, Meylan M, Pupier G, Calvez A, Hernandez I, Sautes-Fridman C. Tertiary lymphoid structures and B cells: an intratumoral immunity cycle. Immunity. 2023;56:2254\u201369.","journal-title":"Immunity"},{"key":"6358_CR15","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.coi.2017.03.006","volume":"45","author":"D Suan","year":"2017","unstructured":"Suan D, Sundling C, Brink R. Plasma cell and memory B cell differentiation from the germinal center. Curr Opin Immunol. 2017;45:97\u2013102.","journal-title":"Curr Opin Immunol"},{"key":"6358_CR16","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1038\/s41590-019-0427-9","volume":"20","author":"K Kwak","year":"2019","unstructured":"Kwak K, Akkaya M, Pierce SK. B cell signaling in context. Nat Immunol. 2019;20:963\u20139.","journal-title":"Nat Immunol"},{"key":"6358_CR17","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.ccell.2023.02.017","volume":"41","author":"CM Laumont","year":"2023","unstructured":"Laumont CM, Nelson BH. B cells in the tumor microenvironment: multi-faceted organizers, regulators, and effectors of anti-tumor immunity. Cancer Cell. 2023;41:466\u201389.","journal-title":"Cancer Cell"},{"key":"6358_CR18","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41568-019-0144-6","volume":"19","author":"C Sautes-Fridman","year":"2019","unstructured":"Sautes-Fridman C, Petitprez F, Calderaro J, Fridman WH. Tertiary lymphoid structures in the era of cancer immunotherapy. Nat Rev Cancer. 2019;19:307\u201325.","journal-title":"Nat Rev Cancer"},{"key":"6358_CR19","doi-asserted-by":"crossref","first-page":"477","DOI":"10.3389\/fimmu.2016.00477","volume":"7","author":"F Barone","year":"2016","unstructured":"Barone F, Gardner DH, Nayar S, Steinthal N, Buckley CD, Luther SA. Stromal fibroblasts in tertiary lymphoid structures: a novel target in chronic inflammation. Front Immunol. 2016;7:477.","journal-title":"Front Immunol"},{"key":"6358_CR20","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/j.tips.2022.09.009","volume":"43","author":"RJ Torphy","year":"2022","unstructured":"Torphy RJ, Yee EJ, Schulick RD, Zhu Y. Atypical chemokine receptors: emerging therapeutic targets in cancer. Trend Pharmacol Sci. 2022;43:1085\u201397.","journal-title":"Trend Pharmacol Sci"},{"key":"6358_CR21","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1186\/s13059-016-1070-5","volume":"17","author":"E Becht","year":"2016","unstructured":"Becht E, Giraldo NA, Lacroix L, Buttard B, Elarouci N, Petitprez F, Selves J, Laurent-Puig P, Sautes-Fridman C, Fridman WH, de Reynies A. Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol. 2016;17:218.","journal-title":"Genome Biol"},{"key":"6358_CR22","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1158\/0008-5472.CAN-13-1342","volume":"74","author":"J Goc","year":"2014","unstructured":"Goc J, Germain C, Vo-Bourgais TK, Lupo A, Klein C, Knockaert S, de Chaisemartin L, Ouakrim H, Becht E, Alifano M, et al. Dendritic cells in tumor-associated tertiary lymphoid structures signal a Th1 cytotoxic immune contexture and license the positive prognostic value of infiltrating CD8+ T cells. Cancer Res. 2014;74:705\u201315.","journal-title":"Cancer Res"},{"key":"6358_CR23","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1038\/nmeth.4402","volume":"14","author":"X Qiu","year":"2017","unstructured":"Qiu X, Mao Q, Tang Y, Wang L, Chawla R, Pliner HA, Trapnell C. Reversed graph embedding resolves complex single-cell trajectories. Nat Method. 2017;14:979\u201382.","journal-title":"Nat Method"},{"key":"6358_CR24","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.ccell.2023.02.015","volume":"41","author":"G Caligiuri","year":"2023","unstructured":"Caligiuri G, Tuveson DA. Activated fibroblasts in cancer: perspectives and challenges. Cancer Cell. 2023;41:434\u201349.","journal-title":"Cancer Cell"},{"key":"6358_CR25","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/j.cell.2023.02.020","volume":"186","author":"DJ Kloosterman","year":"2023","unstructured":"Kloosterman DJ, Akkari L. Macrophages at the interface of the co-evolving cancer ecosystem. Cell. 2023;186:1627\u201351.","journal-title":"Cell"},{"key":"6358_CR26","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1038\/ncomms3612","volume":"4","author":"K Yoshihara","year":"2013","unstructured":"Yoshihara K, Shahmoradgoli M, Martinez E, Vegesna R, Kim H, Torres-Garcia W, Trevino V, Shen H, Laird PW, Levine DA, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4:2612.","journal-title":"Nat Commun"},{"key":"6358_CR27","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","volume":"77","author":"A Kamoun","year":"2020","unstructured":"Kamoun A, de Reynies A, Allory Y, Sjodahl G, Robertson AG, Seiler R, Hoadley KA, Groeneveld CS, Al-Ahmadie H, Choi W, et al. A consensus molecular classification of muscle-invasive bladder cancer. Eur Urol. 2020;77:420\u201333.","journal-title":"Eur Urol"},{"key":"6358_CR28","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.clgc.2020.02.014","volume":"18","author":"G Iyer","year":"2020","unstructured":"Iyer G, Tully CM, Zabor EC, Bochner BH, Dalbagni G, Herr HW, Donat SM, Russo P, Ostrovnaya I, Regazzi AM, et al. Neoadjuvant gemcitabine-cisplatin plus radical cystectomy-pelvic lymph node dissection for muscle-invasive bladder cancer: a 12\u00a0year experience. Clin Genitourin Cancer. 2020;18:387\u201394.","journal-title":"Clin Genitourin Cancer"},{"key":"6358_CR29","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1038\/s41591-023-02568-1","volume":"29","author":"MD Galsky","year":"2023","unstructured":"Galsky MD, Daneshmand S, Izadmehr S, Gonzalez-Kozlova E, Chan KG, Lewis S, Achkar BE, Dorff TB, Cetnar JP, Neil BO, et al. Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial. Nat Med. 2023;29:2825\u201334.","journal-title":"Nat Med"},{"key":"6358_CR30","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.euf.2024.05.015","volume":"10","author":"E Day","year":"2024","unstructured":"Day E, Gavira J, Tapia JC, Anguera G, Maroto P. What about variant histologies in bladder cancer? Eur Urol Focus. 2024;10:227\u201330.","journal-title":"Eur Urol Focus"},{"key":"6358_CR31","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.eururo.2020.02.028","volume":"77","author":"A Necchi","year":"2020","unstructured":"Necchi A, Raggi D, Gallina A, Ross JS, Fare E, Giannatempo P, Marandino L, Colecchia M, Luciano R, Bianchi M, et al. Impact of molecular subtyping and immune infiltration on pathological response and outcome following neoadjuvant pembrolizumab in muscle-invasive bladder cancer. Eur Urol. 2020;77:701\u201310.","journal-title":"Eur Urol"},{"key":"6358_CR32","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ccr.2014.01.009","volume":"25","author":"W Choi","year":"2014","unstructured":"Choi W, Porten S, Kim S, Willis D, Plimack ER, Hoffman-Censits J, Roth B, Cheng T, Tran M, Lee IL, et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell. 2014;25:152\u201365.","journal-title":"Cancer Cell"},{"issue":"540\u2013556","key":"6358_CR33","volume":"171","author":"AG Robertson","year":"2017","unstructured":"Robertson AG, Kim J, Al-Ahmadie H, Bellmunt J, Guo G, Cherniack AD, Hinoue T, Laird PW, Hoadley KA, Akbani R, et al. Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell. 2017;171(540\u2013556): e525.","journal-title":"Cell"},{"issue":"72","key":"6358_CR34","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.eururo.2017.03.030","volume":"2017","author":"R Seiler","year":"2017","unstructured":"Seiler R, Ashab HAD, Erho N, van Rhijn BWG, Winters B, Douglas J, Van Kessel KE, Fransen van de Putte EE, Sommerlad M, Wang NQ, et al. Impact of molecular subtypes in muscle-invasive bladder cancer on predicting response and survival after neoadjuvant chemotherapy. Eur Urol. 2017;2017(72):544\u201354.","journal-title":"Eur Urol"},{"key":"6358_CR35","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1038\/s41467-023-37568-9","volume":"14","author":"AG Robertson","year":"2023","unstructured":"Robertson AG, Meghani K, Cooley LF, McLaughlin KA, Fall LA, Yu Y, Castro MAA, Groeneveld CS, de Reynies A, Nazarov VI, et al. Expression-based subtypes define pathologic response to neoadjuvant immune-checkpoint inhibitors in muscle-invasive bladder cancer. Nat Commun. 2023;14:2126.","journal-title":"Nat Commun"},{"key":"6358_CR36","doi-asserted-by":"publisher","DOI":"10.1126\/science.abf9419","author":"TN Schumacher","year":"2022","unstructured":"Schumacher TN, Thommen DS. Tertiary lymphoid structures in cancer. Science. 2022. https:\/\/doi.org\/10.1126\/science.abf9419.","journal-title":"Science"},{"key":"6358_CR37","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/s41571-022-00619-z","volume":"19","author":"WH Fridman","year":"2022","unstructured":"Fridman WH, Meylan M, Petitprez F, Sun CM, Italiano A, Sautes-Fridman C. B cells and tertiary lymphoid structures as determinants of tumour immune contexture and clinical outcome. Nat Rev Clin Oncol. 2022;19:441\u201357.","journal-title":"Nat Rev Clin Oncol"},{"key":"6358_CR38","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/j.jcmgh.2021.06.023","volume":"12","author":"FR Delvecchio","year":"2021","unstructured":"Delvecchio FR, Fincham REA, Spear S, Clear A, Roy-Luzarraga M, Balkwill FR, Gribben JG, Bombardieri M, Hodivala-Dilke K, Capasso M, Kocher HM. Pancreatic cancer chemotherapy is potentiated by induction of tertiary lymphoid structures in mice. Cell Mol Gastroenterol Hepatol. 2021;12:1543\u201365.","journal-title":"Cell Mol Gastroenterol Hepatol"},{"issue":"1370\u20131385","key":"6358_CR39","volume":"42","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Liu G, Zeng Q, Wu W, Lei K, Zhang C, Tang M, Zhang Y, Xiang X, Tan L, et al. CCL19-producing fibroblasts promote tertiary lymphoid structure formation enhancing anti-tumor IgG response in colorectal cancer liver metastasis. Cancer Cell. 2024;42(1370\u20131385): e1379.","journal-title":"Cancer Cell"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-06358-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-025-06358-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-06358-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T00:42:29Z","timestamp":1743122549000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-025-06358-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,27]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6358"],"URL":"https:\/\/doi.org\/10.1186\/s12967-025-06358-w","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,27]]},"assertion":[{"value":"1 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by National Cancer Center\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (approval #20\/084-2280). All investigations carried out in this study were performed in accordance with the tenets of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Each patient enrolled in this study provided written informed consent. All authors have read and approved the manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"375"}}